FoodChain ID and Agmatix Partner to Advance Regenerative Agriculture with AI-Powered Certification
30.9.2025 13:00:00 CEST | Business Wire | Press Release
FoodChain ID, a global leader in sustainability certification and food technology services, and Agmatix, an agtech company pioneering data-driven agronomic intelligence, announce their strategic collaboration to accelerate regenerative agriculture with measurable return-on-investment. The partnership responds to the growing demand for trusted, transparent, and outcome-focused approaches to regenerative agriculture by providing companies with certification credibility and data-driven actionable insights.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930435032/en/
FoodChain ID and Agmatix partner to meet the growing demand for trusted, transparent, and outcome-focused approaches to regenerative agriculture by providing companies with certification credibility and data-driven actionable insights.
Through the partnership, FoodChain ID’s certification customers will have access to RegenIQ, Agmatix’s proprietary AI-powered model designed to accelerate regenerative agriculture adoption. RegenIQ enables companies to evaluate, prioritize and monitor regenerative practices across their operations, empowering companies to prioritize actions that deliver measurable environmental and economic results. In turn, Agmatix’s clients benefit from FoodChain ID’s global Regenerative Agriculture Certification, an independent, science-based certification standard. As a leader in global certifications, FoodChain ID offers measurable, tiered frameworks for producers and food brands seeking to implement and scale sustainable agriculture systems.
Dr. Chetan Parmar, Senior Vice President of Technical Services for Europe and Asia at FoodChain ID, explains, “FoodChain ID brings nearly 30 years of experience in sustainability services and our technology background to our partnership with Agmatix. Throughout our history, we have demonstrated the importance of a transparent food supply chain and are excited to show the return-on-investment for regenerative systems.”
FoodChain ID’s Regenerative Agriculture Certification, based on ISO 17065 principles, allows farmers across diverse geographies and production systems to adopt regenerative farming practices. Regenerative agriculture aims to ensure healthy soils, increase biodiversity, restore ecosystem balance and mitigate the acceleration of climate change while enabling farmers to create a sustainable business.
Agmatix developed RegenIQ to help agri-food sector companies identify which practices deliver the greatest combined impact by balancing agronomic performance, sustainability goals and economic outcomes. By leveraging standardized agronomic data, predictive AI, and modeling, RegenIQ provides decision-making support that turns regenerative commitments into measurable improvements.
“Certification is essential to building trust in regenerative agriculture, but companies also need data-driven insights to make meaningful change,” said Ron Baruchi, CEO of Agmatix. “This collaboration bridges both needs, giving companies a credible path to certification and a way to maximize the outcomes of their investments in regenerative agriculture.”
About FoodChain ID
FoodChain ID is a trusted provider to over 30,000 companies across the global supply chain. The company delivers technology-enabled solutions and technical expertise to keep the food supply chain safe, compliant and transparent. Service areas include product development, regulatory compliance, food safety certification, product certification and testing. Visit www.FoodChainID.com for more information.
About Agmatix
Agmatix is a global agtech company transforming agronomic data into actionable intelligence. Headquartered in Durham, North Carolina, its proprietary Axiom platform and RegenIQ model harness standardized data, predictive analytics, and AI to help agronomists, food companies, and ag retailers drive sustainable practices and outcomes across the agricultural value chain. Learn more at www.agmatix.com and www.regeniq.earth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250930435032/en/
Contacts
Gina Axel
Growers
gina.axel@growers.ag
+1 315-719-1335
Ceci Snyder
FoodChain ID
csnyder@foodchainid.com
+1 515-491-5173
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press Release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom